Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Increase in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 111,100 shares, an increase of 439.3% from the March 15th total of 20,600 shares. Based on an average daily trading volume, of 216,900 shares, the days-to-cover ratio is presently 0.5 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded down $0.01 during trading hours on Wednesday, hitting $17.71. The stock had a trading volume of 681,150 shares, compared to its average volume of 127,736. The company has a market capitalization of $58.27 billion, a P/E ratio of 25.31 and a beta of 0.78. The firm's 50-day moving average price is $19.36 and its two-hundred day moving average price is $17.86. Chugai Pharmaceutical has a 52 week low of $11.93 and a 52 week high of $22.61.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.01. The firm had revenue of $1.85 billion during the quarter. Chugai Pharmaceutical had a return on equity of 21.02% and a net margin of 29.14%. As a group, analysts expect that Chugai Pharmaceutical will post 0.7 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.